Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610414 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,877
- Enrollment target
NCT01610414 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,877 participants.
The verdict
NCT01610414, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,877 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in reducing the risk of developing HZ in this population.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Herpes Zoster vaccine GSK1437173A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,877 participants |
| Start Date | 2012-07-13 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610414
The ClinicalTrials.gov registry entry for NCT01610414 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,877 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01610414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01610414 about?
NCT01610414 is a clinical study titled "Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A". The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vacci...
What is the current status of trial NCT01610414?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,877 participants. The study started on 2012-07-13. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01610414?
The interventions under investigation include: Placebo (BIOLOGICAL), Herpes Zoster vaccine GSK1437173A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01610414?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.